Turquoise’s latest podcast: Chinese Outbound M&A

In our latest podcast, Turquoise managing director Ian Thomas interviews colleagues Francis Wright (managing director) and David Wright (director, China) on all matters Chinese outbound M&A. Turquoise advises Chinese corporates on acquisitions in the UK and Europe. The podcast covers key insights from the team, including: The opportunities Chinese companies are seeking with outbound M&A…

Low Carbon Innovation Fund 2 invests in bio-bean

Turquoise, the UK merchant bank specialising in energy, environment and efficiency, has invested in bio-bean for the Low Carbon Innovation Fund 2 (LCIF2). The investment of £350,000 is part of an overall round of £1.25million.  The round was led by LCIF2 with the participation of 2Enable Partners, Stellar Impact and the Gresham House Renewable Energy…

EG Group Invest in Hydrogen Vehicle Systems (HVS)

Scotland-based HV Systems (HVS) has secured a £5 million capital injection from Beehive Equity Limited, a wholly-owned subsidiary of EG Group (EG). Multiple award-winning HVS will now take its innovative hydrogen vehicle designs through prototyping and demonstration, allowing manufacturing to commence. There has been much said about impending bans on the sale of new petrol…

Turquoise advises Zhejiang Jiecang Linear Motion Technology on its €79.18m acquisition of Logicdata

Turquoise International (“Turquoise”) is pleased to announce that Zhejiang Jiecang Linear Motion Technology (“Jiecang”) has agreed to acquire Logicdata Elektronik and Software Entwicklungs GmbH (“Logicdata”). Turquoise acted as financial adviser to Jiecang which acquired 100% of Logicdata for €79.18m. This merger will create a leading worldwide linear motion components and systems supplier with annual revenue…

Low Carbon Innovation Fund 2 invests in Ablatus Therapeutics

Turquoise, the UK merchant bank specialising in energy, environment and efficiency, has invested in Ablatus Therapeutics for the Low Carbon Innovation Fund 2 (LCIF2). The investment of £85,000 is part of an overall round which could reach £1.5million. Ablatus Therapeutics is developing Bimodal Electric Tissue Ablation (BETA), an innovative improvement over existing tissue ablation techniques,…

Meet the team: John Loughhead

We are very pleased to announce that Professor John Loughhead, until recently Chief Scientific Adviser to the Department for Business, Energy and Industrial Strategy (BEIS), has agreed to become the Independent Member of the Investment Committee of the Low Carbon Innovation Fund 2 (LCIF2). What has been the most significant technological development of recent years? There…